title: Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma.
abstract: OBJECTIVE
  To evaluate the performance of dynamic contrast enhanced (DCE) magnetic resonance (MR) imaging to assess the histological response after chemotherapy on bladder carcinoma.
  
  
  METHODS
  From 2008 to 2010, 12 patients presenting localized urothelial carcinoma of the bladder were prospectively evaluated by DCE-MR imaging before and after two courses of cisplatin-based neoadjuvant chemotherapy. Size and thickness of tumours were measured. Relative enhancement at the arterial (rSI35s) and venous phases (rSI80s) of each tumour was obtained. Histological response was assessed and outcomes were recorded.
  
  
  RESULTS
  Histological examination after neoadjuvant chemotherapy concluded as pathological complete response (pCR) for 6 out of 12 patients. Five patients developed recurrences (4/6 no pCR and 1/6 pCR). Significant differences, between before and after treatment, were found for patients with complete pathological response after chemotherapy for all MR quantitative values. Tumours decreased in size and thickness (both P=0.03). After treatment, rSI80s was significantly different between pCR and non-pCR patients (P=0.04) with a cut-off value of 40%. For this cut-off, sensitivity, specificity and accuracy were 83.33%. Similar recurrence free survivals were obtained if applying the MR cut-off value or the histopathological findings.
  
  
  CONCLUSIONS
  Our results suggest that DCE-MR imaging may be a useful biomarker for patients with localized bladder carcinoma, improving selection before surgery.
authors: Department of Medical Oncology, Bergonié Cancer Institute, Bordeaux, France.
authors: Camille
authors: C
authors: Chakiba
authors: Department of Radiology, Pellegrin Hospital, Bordeaux, France.
authors: François
authors: F
authors: Cornelis
authors: Department of Radiology, Saint-Augustin Clinic, Bordeaux, France.
authors: Edouard
authors: E
authors: Descat
authors: Department of Medical Oncology, Bergonié Cancer Institute, Bordeaux, France.
authors: Marine
authors: M
authors: Gross-Goupil
authors: Department of Radiotherapy, Bergonié Cancer Institute, Bordeaux, France.
authors: Paul
authors: P
authors: Sargos
authors: Department of Medical Oncology, Bergonié Cancer Institute, Bordeaux, France.
authors: Guilhem
authors: G
authors: Roubaud
authors: Department of Medical Oncology, Bergonié Cancer Institute, Bordeaux, France; Department of Medical Oncology, Nimes University Hosptital, Nîmes, France. Electronic address: nadine.houede@chu-nimes.fr.
authors: Nadine
authors: N
authors: Houédé
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D003287:Contrast Media; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009364:Neoplasm Recurrence, Local; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
chemical_list: D015415:Biomarkers; D003287:Contrast Media
keywords: Biomarker; Bladder carcinoma; Contrast; MRI; Neoadjuvant chemotherapy; Therapeutic response